Seeking Alpha

Seeking Alpha Portfolio App for iPad

769 people get PLX articles and Market Currents by email alert.

Get email alerts on PLX »

PLX

Protalix BioTherapeutics, Inc

5/21/2013, 9:46 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 29, 8:18 AM Protalix BioTherapeutics (PLX) rises 6% premarket as its Type I Gaucher disease treatment UPLYSO ("ELELYSO" outside of Latin America) gains approval in Mexico and Chile — it is already approved in the U.S., Israel, and Brazil. The company develops and commercializes the drug with Pfizer (PFE). (PR) Comment! [Healthcare, On the Move]
Tuesday, April 2, 8:08 AM Protalix BioTherapeutics (PLX) says the first patient has been treated in a phase 1 clinical trial of its orally-administered treatment for Gaucher disease. The phase 1 trial should be completed during Q3 of this year. Shares +1.5% premarket. Comment! [Healthcare]
Monday, March 18, 3:22 PM Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian health authorities had given regulatory approval to Uplyso, a long-term enzyme replacement therapy for adults with Type I Gaucher disease. PLX has partnered with Pfizer (PFE +0.3%) to market and commercialise the drug worldwide, apart from Israel where it maintains exclusive rights. Comment! [Healthcare, On the Move, Global & FX]
Tuesday, February 5, 1:00 PM Midday top 10 gainers: OPXA +189%. CEP +31%. SCKT +23%. PLX +18%. CPSS +18%. VMED +17%. TRT +17%. STV +16%. BCOM +15%. CNR +15%.
Midday top 10 losers: DCIX -13%. IEC -13%. PRPH -11%. BIDU -11%. ACI -11%. PGRX -10%. JAXB -10%. DFZ -10%. RTEC -9%. SGMS -9%. Comment! [On the Move]
Tuesday, February 5, 9:44 AM Protalix (PLX) surges 14.2% following an Israeli report that Pfizer has shown an interest in buying the company after it hired Citigroup to start a sale process. Protalix is angling for $1B, double its market cap, although Pfizer doesn't want to pay that much, while an offer of $700-800M could be enough to sway Protalix's largest shareholders. The companies already partner for the marketing of Protalix's Elelyso drug for Gaucher disease. Comment! [Healthcare, On the Move, M&A]
Monday, December 10, 2012, 10:24 AM Protalix BioTherapeutics (PLX +0.7%) says its the first patient has been treated in its Phase I/II clinical trials of PRX-102, its plant cell-expressed, chemically modified enzyme replacement therapy for the treatment of Fabry disease. Comment! [Healthcare, On the Move]
Thursday, December 6, 2012, 8:33 AM Protalix (PLX +5.5%) signs an agreement with Pfizer (PFE) in which the latter will conduct and sponsor new trials for Protalix's Elelyso treatment for Gaucher disease, which stops cells and organs from working properly. Protalix will be eligible to receive milestone payments of up $8.3M; the company will continue to conduct existing trials of Elelyso. (PR) 3 Comments [Healthcare, On the Move]
Monday, June 25, 2012, 10:49 AM Protalix (PLX -3.7%) slips after being downgraded to Market Perform at Wells Fargo, citing the CHMP's rejection of Elelyso - despite the drug's favorable benefits - in deference to Shire's Orphan exclusivity status for Vpriv. The firm also lowers its price range to $6 - $8 from $9 - $11. Comment! [Healthcare, On the Move]
Friday, June 22, 2012, 9:26 AM Protalix Biotherapeutics (PLX) -16.7% premarket after saying European medical authorities have ruled against recommending taliglucerase alfa, an enzyme replacement therapy for treatment of Gaucher disease developed by PLX and its partner Pfizer (PFE). Comment! [Healthcare, On the Move]
Friday, June 22, 2012, 9:10 AM Premarket gainers: HNR +82%. ALXA +19%. NPSP +9%.
Losers: PLX -12%. R -10%. 2 Comments [On the Move]
Wednesday, May 2, 2012, 12:14 PM Canaccord takes some of the shine off Protalix's (PLX +13%) early morning 27% run-up in the wake of the FDA's approval of its new treatment for Gaucher disease, downgrading the shares to Hold after digging deeper into the report. The firm says it sees only modest U.S. but solid Israel/ROW potential, and EU approval may in fact be blocked. Comment! [Healthcare, On the Move]
Wednesday, May 2, 2012, 9:00 AM Premarket gainers: SMSC +38%. CHRS +24%. PLX +22%. TRIP +16%. ASNA +13%. PCO +13%. ESIC +13%. AEO +9%. DCIX +8%. WCG +9%. OCZ +8%. HLF +6%. GNW +4%. REXX +3%. CBS +3%. UBS +3%.
Losers: OPEN -15%. CHK -10%. STD -7%. VE -5%. TEF -5%. CS -5%. NOK -4%. TS -4%. DB -4%. NBG -4%. CMCSA -4%. FTE -3%. ERIC -3%. SI -3%. Comment! [On the Move]
Tuesday, May 1, 2012, 4:32 PM Protalix BioTherapeutics (PLX) +22.8% AH after the FDA approves the company's new orphan drug to treat a form of Gaucher disease. Comment! [Healthcare, On the Move]
Monday, April 30, 2012, 9:10 AM Premarket gainers: BKS +92%. DMD +38%. SUN +21%. WCRX +20%. GPRO +20%. XOMA +9%. IOC +5%. MNKD +5%. PLX +4%. ARNA +4%. AMRN +3%.
Losers: LDK -14%. SOHU -8%. GNC -5%. HUM -5%. HOLX -4%. SINA -3%. Comment! [On the Move]
Monday, April 23, 2012, 9:05 AM Premarket gainers: RDEA +51%. CEDC +20%. KERX +16%. AMLN +12%. PLX +5%.
Losers: ACHN -14%. ING -7%. CHKP -6%. MT -5%. MT -5%. DB -5%. WMT -5%. AKS -4%. RIO -4%. FSLR -4%. BAC -4%. EPI -4%. TOT -3%. ERIC -3%. NG -3%. FCX -3%. TEF -3%. F -3%. CS -3%. MS -3%. X -3%. RVBD -3%. AMD -3%. 1 Comment [On the Move]
Thursday, February 16, 2012, 12:44 PM Protalix BioTherapeutics (PLX -10.6%) says its sale of 4.5M shares priced at $5.25 per share, a 14% discount to yesterday's close. Comment! [Healthcare, On the Move]